ABC News logo
Associated Press logo
The Independent logo
24 articles
·10M

Biden Administration Proposes $35 Billion Coverage for Anti-Obesity Drugs Amid Challenges from Incoming Trump Officials

The Biden administration's rule seeks to allow Medicare and Medicaid coverage for anti-obesity medications, but faces potential opposition and budget concerns.

Subscribe to unlock this story

We really don't like cutting you off, but you've reached your monthly limit. At just $5/month, subscriptions are how we keep this project going. Start your free 7-day trial today!

Get Started

Have an account? Sign in

Overview

A summary of the key points of this story verified across multiple sources.

On November 26, 2024, the Biden administration proposed a $35 billion plan to cover anti-obesity drugs like Wegovy and Zepbound under Medicare and Medicaid, potentially benefiting millions. However, the rule, requiring Congressional approval, faces skepticism from incoming Trump administration officials, particularly Robert F. Kennedy Jr., who opposes the drugs. While a bipartisan coalition supports the initiative, concerns regarding its high cost and the necessity of price negotiations with manufacturers persist among some lawmakers.

Written by AI using shared reports from
24 articles
.

Report issue

Pano Newsletter

Read both sides in 5 minutes each day

Analysis

Compare how each side frames the story — including which facts they emphasize or leave out.

Analysis unavailable for this viewpoint.

Articles (24)

Compare how different news outlets are covering this story.

History

See how this story has evolved over time.

  • 10M
    PBS NewsHour logo
    ABC News logo
    Roll Call logo
    4 articles
  • 10M
    ABC News logo
    NBC News logo
    CNN logo
    4 articles